

1. Supplementary information

1.1 FMIA assay specifications and thresholds for positivity

Assay specificity and sensitivity were determined by analysing sera (n=402) collected in mid-2019 (negative controls) and sera collected in 2020 from subjects (n=87) with PCR-confirmed COVID-19 14-51 days after symptom onset and no COVID-19 vaccination history (positive controls). The positive control sample material has been previously described¹. Samples collected from April to September 2020 (n=3954) were only analysed for N-IgG, and the samples thereafter were analysed for N-IgG and S-IgG (n=5840).

Samples collected from April 2020 to December 2021 (n=7039) were analysed as duplicates diluted 1:100. The threshold for N-IgG positivity during this period was >6.7 BAU/ml resulting in 100% specificity and 95.8% sensitivity. Samples with >0.9 BAU/ml IgG to receptor binding domain and >1.6 BAU/ml IgG to full-length spike glycoprotein were considered S-IgG positive and the assay specificity and sensitivity were 100%.

Samples collected in 2022 (n=2755) were analysed as duplicates diluted 1:100 and 1:1600. The threshold for N-IgG positivity during this period was >7 BAU/ml resulting in 92.8% specificity and 100% sensitivity. Samples with >3 BAU/ml IgG to receptor binding domain and >2 BAU/ml IgG to full-length spike glycoprotein were considered S-IgG positive, and the assay specificity and sensitivity were 100%.

1.2 Supplementary references

1. Dub, T. *et al.* High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020-2021. *Front. Med.* **9**, 876532 (2022).

1.3 Tables

Table S1. Description of the random population surveys

Survey	Week/year	Sample size total/per district	Invited subjects	Participated subjects	Participation rate	Healthcare district
1	14/2020	750	733	468	64%	HUS
2	15/2020	750	728	451	62%	HUS
3	16/2020	1000/200	989	509	51%	All five
4	17/2020	1000/200	980	469	48%	All five
5	17/2020	1000/200	980	480	49%	All five
6	18/2020	750/150	738	313	42%	All five
7	19/2020	400/80	392	162	41%	All five
8	21/2020	400/80	394	145	37%	All five
9	22/2020	400/80	398	171	43%	All five
10	22/2020	900/500 [§] /80	876	314	36%	All five
11	25/2020	400/80	391	132	34%	All five
12	29/2020	400/80	391	130	33%	All five
13	31/2020	400/80	396	138	35%	All five
14	33/2020	400*	392	113	29%	All five
15	35/2020	400*	390	113	29%	All five
16	37/2020	400*	392	112	29%	All five
17	39/2020	400*	387	113	29%	All five
18	41/2020	400*	392	107	27%	All five
19	43/2020	400*	392	104	27%	All five
20	45/2020	600* [#]	599	174	29%	All five
21	47/2020	600* [#]	600	170	28%	All five
22	49/2020	600* [#]	601	171	28%	All five
23	52/2020	600* [#]	594	164	28%	All five
24	02/2021	600* [#]	595	160	27%	All five
25	05/2021	600* [#]	597	192	32%	All five
26	07/2021	600* [#]	588	178	30%	All five
27	09/2021	600* [#]	594	184	31%	All five
28	11/2021	400	382	111	29%	HUS
29	14/2021	600* [#]	599	181	30%	All five
30	15/2021	400	391	119	30%	HUS
31	17/2021	600* [#]	601	147	24%	All five
32	19/2021	400	390	101	26%	HUS
33	21/2021	600* [#]	603	123	20%	All five
34	23/2021	400	385	83	22%	HUS
35	27/2021	400	386	86	22%	HUS
36	41/2021	750	728	153	21%	HUS
37	10/2022	2500	2426	377	16%	HUS
38	17/2022	2500	2424	458	19%	HUS
39	19/2022	4000/1000	3929	731	19%	All excl. HUS
40	40/2022	6500/2500 [§] /1000	6358	1190	19%	All five

HUS= Helsinki and Uusimaa healthcare district

*sample size per district adjusted by population

sample size for HUS district doubled

§ sample size for HUS district

Table S2. The number of participants per year and month.

		2020	2021	2022
Q1	January	0	53	1
	February	0	413	0
	March	0	418	168
Q2	April	1460	314	87
	May	1305	319	456
	June	685	215	791
Q3	July	201	43	38
	August	244	83	14
	September	242	3	8
Q4	October	245	13	258
	November	261	132	879
	December	382	10	53

Table S3. Study population compared to Uusimaa region and Finland's 18-85-year-old population structure at the end of 2021.

		Study population n=9794	Uusimaa, Finland, 18-85-year-olds (n=1.35 million)	Whole Finland, 18-85-year-olds (n=4.36 million)
Age	18-29	11%	19%	18 %
	30-44	25%	29%	25 %
	45-64	44%	32%	32 %
	65-85	19% ^a	21%	26 %
Sex	Female	61%	51%	50 %
	Male	39%	49%	50 %
Native language	Finnish or Swedish	97%	85%	91 %
	Other	3%	15%	9 %
	Reside in Uusimaa	54%	100%	31%
Vaccinated for COVID-19 ^b		96% ^d	88%	88%
Registered COVID-19 cases ^c		2518 (26%) ^e	457 528 (34%)	1 219 008 (28%)

^a 65-70-year-olds in 2021-2021 and 65-85-year-olds in 2022.

^b Have received at least one COVID-19 vaccine dose before 15th of December 2021, i.e. would have developed vaccine-mediated immunity by 2022.

^c January 1st 2020 to December 31st 2022.

^d Vaccinated before or after sample collection.

^e Case registered before or after sample collection.

Table S4. The number of serological samples collected in Finland's different healthcare districts per year quartile.

Number of participants per healthcare district, % of the quartile's samples						
Year	Quartile	Helsinki and Uusimaa (HUS)	Pirkanmaa	Northern Ostrobothnia	Northern Savonia	Southwest Finland
2020	Q2, n=3450	46% (n=1603)	15% (n=517)	12% (n=420)	14% (n=481)	12% (n=429)
	Q3, n=687	35% (n=242)	20% (n=135)	16% (n=107)	13% (n=88)	17% (n=115)
	Q4, n=888	65% (n=580)	13% (n=114)	7% (n=63)	7% (n=62)	8% (n=69)
2021	Q1, n=884	70% (n=618)	11% (n=101)	7% (n=62)	4% (n=37)	7% (n=66)
	Q2, n=847	83% (n=705)	6% (n=50)	5% (n=44)	3% (n=22)	3% (n=26)
	Q3, n=129	96% (n=124)	3% (n=4)	1% (n=1)	0% (n=0)	0% (n=0)
	Q4, n=155	100% (n=155)	0% (n=0)	0% (n=0)	0% (n=0)	0% (n=0)
2022	Q1, n=169	100% (n=169)	0% (n=0)	0% (n=0)	0% (n=0)	0% (n=0)
	Q2, n=1335	48% (n=645)	13% (n=179)	11% (n=152)	14% (n=193)	12% (n=166)
	Q3, n=60	33% (n=20)	20% (n=12)	5% (n=3)	15% (n=9)	27% (n=16)
	Q4, n=1190	38% (n=451)	16% (n=191)	16% (n=188)	17% (n=202)	13% (n=158)
Total, n=9794		54% (n=5312)	13% (n=1303)	11% (n=1040)	11% (n=1094)	11% (n=1045)

Table S5. N-IgG and S-IgG seropositivity by year quartile and age group.

Year	Quartile	Analysed samples, n	Age	N-IgG positives %, (n)	S-IgG positives %, (n)
2020	Q2	N-IgG:3450 S-IgG:0	18-29	0.8% (4/523)	NA (0/0)
			30-44	2.3% (23/1005)	NA (0/0)
			45-64	2.2% (35/1562)	NA (0/0)
			65-70	3.1% (11/360)	NA (0/0)
	Q3	N-IgG:687 S-IgG:183	18-29	4.5% (3/66)	0.0% (0/10)
			30-44	2.9% (6/204)	4.8% (3/62)
			45-64	2.2% (7/317)	2.3% (2/88)
			65-70	5.0% (5/100)	0.0% (0/23)
	Q4	N-IgG:888 S-IgG:888	18-29	6.0% (7/117)	3.4% (4/117)
			30-44	2.2% (6/269)	0.7% (2/269)
			45-64	2.8% (11/390)	1.5% (6/390)
			65-70	0.0% (0/112)	0.0% (0/112)
2021	Q1	N-IgG:884 S-IgG:884	18-29	2.7% (3/112)	4.5% (5/112)
			30-44	2.4% (6/249)	5.2% (13/249)
			45-64	3.6% (15/419)	6.9% (29/419)
			65-70	1.9% (2/104)	4.8% (5/104)
	Q2	N-IgG:847 S-IgG:847	18-29	4.7% (6/127)	13.4% (17/127)
			30-44	7.3% (17/232)	27.6% (64/232)
			45-64	4.8% (19/399)	51.1% (204/399)
			65-70	3.4% (3/89)	74.2% (66/89)
	Q3	N-IgG:129 S-IgG:129	18-29	0.0% (0/10)	70.0% (7/10)
			30-44	6.3% (3/48)	77.1% (37/48)
			45-64	3.6% (2/55)	90.9% (50/55)
			65-70	0.0% (0/16)	93.8% (15/16)
Q4	N-IgG:155 S-IgG:155	18-29	7.1% (1/14)	92.9% (13/14)	
		30-44	0.0% (0/41)	82.9% (34/41)	
		45-64	12.8% (10/78)	89.7% (70/78)	
		65-70	4.5% (1/22)	100.0% (22/22)	
2022	Q1	N-IgG:169 S-IgG:169	18-29	33.3% (3/9)	100.0% (9/9)
			30-44	41.2% (14/34)	100.0% (34/34)
			45-64	30.4% (21/69)	100.0% (69/69)
			65-85	19.3% (11/57)	100.0% (57/57)
	Q2	N-IgG:1335 S-IgG:1335	18-29	55.4% (41/74)	95.9% (71/74)
			30-44	44.9% (96/214)	95.3% (204/214)
			45-64	35.6% (195/548)	98.2% (538/548)
			65-85	27.9% (139/499)	99.6% (497/499)
	Q3	N-IgG:60 S-IgG:60	18-29	100.0% (4/4)	100.0% (4/4)
			30-44	64.3% (9/14)	92.9% (13/14)
			45-64	38.7% (12/31)	100.0% (31/31)
			65-85	36.4% (4/11)	100.0% (11/11)
Q4	N-IgG:1190 S-IgG:1190	18-29	71.2% (37/52)	98.1% (51/52)	
		30-44	55.8% (96/172)	97.7% (168/172)	
		45-64	53.6% (241/450)	98.9% (445/450)	
		65-85	39.7% (205/516)	99.2% (512/516)	